<DOC>
	<DOCNO>NCT00614549</DOCNO>
	<brief_summary>To evaluate , 1 year period , efficacy safety newly prescribe levetiracetam add-on treatment ( POS , myoclonoc seizure JME PGTCS IGE ) primary monotherapy ( partial onset seizure ) adult paediatric patient within approved age limit routine clinical practice Czech Slovak Republics , Hungary , Romania . Non-interventional study .</brief_summary>
	<brief_title>Efficacy Safety Levetiracetam Routine Clinical Practice Czech Slovak Republics , Hungary , Romania .</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>diagnosis partial onset seizure ( POS ) without secondary generalisation Juvenile Myoclonic Epilepsy ( JME ) another IGE PGTCS newly prescribe levetiracetam addon treatment ( POS , myoclonic seizure JME PGTCS IGE ) monotherapy ( partial onset seizure ) newly diagnose patient . Newly prescribe mean inclusion patient decision make prescribe LEV first dose prescribe . age 4 year partial onset seizure , 12 year MS JME PGTCS IGE , 16 year monotherapy patient write informed consent indication define inclusion criterion history allergic anaphylactic reaction levetiracetam pyrrolidone derivative excipients include</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Levetiracetam</keyword>
	<keyword>Keppra</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
</DOC>